{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:05:31Z","timestamp":1776920731181,"version":"3.51.2"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare nilotinib concentrations obtained by venous blood sampling and dried blood spot (DBS) in patients with chronic myeloid leukaemia (CML). It was investigated how to predict nilotinib plasma levels on the basis of DBS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Forty duplicate DBS and venous blood samples were collected from 20 patients. Capillary blood was obtained by finger prick and spotted on DMPK-C Whatman sampling paper, simultaneously with venous blood sampling. Plasma concentrations were predicted from DBS concentrations using three methods: (1) individual and (2) mean haematocrit correction and (3) the bias between plasma and DBS concentrations. Results were compared using Deming regression and Bland\u2013Altman analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Nilotinib plasma concentrations ranged from 376 to 2663 \u03bcg\/l. DBS concentrations ranged from 144 to 1518 \u03bcg\/l. The slope was 0.56 (95% CI, 0.51 to 0.61) with an intercept of \u221241.68 \u03bcg\/l (95% CI, \u221293.78 to 10.42). Mean differences between calculated and measured plasma concentrations were \u221214.3% (method 1), \u221214.0% (method 2) and \u22120.6% (method 3); differences were within 20% of the mean in 73%, 85% and 80% of the samples, respectively. The slopes were respectively 0.96 (95% CI, 0.86 to 1.06), 0.95 (95% CI, 0.86 to 1.03) and 1.00 (95% CI, 0.91 to 1.09).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Plasma concentrations of nilotinib could be predicted on the basis of DBS. DBS sampling to assess nilotinib concentrations in CML patients seems a suitable alternative for venous sampling.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12757","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T07:16:52Z","timestamp":1498202212000},"page":"1265-1274","source":"Crossref","is-referenced-by-count":33,"title":["Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling"],"prefix":"10.1093","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-3612","authenticated-orcid":false,"given":"Christel C L M","family":"Boons","sequence":"first","affiliation":[{"name":"Cancer Center Amsterdam, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center , Amsterdam,","place":["The Netherlands"]},{"name":"Amsterdam Public Health research institute, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel","family":"Chahbouni","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneliene M","family":"Schimmel","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham J","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne M","family":"den Hartog","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Department of Haematology, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J W M","family":"Janssen","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Department of Haematology, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N Harry","family":"Hendrikse","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center , Amsterdam,","place":["The Netherlands"]},{"name":"Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline G","family":"Hugtenburg","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center , Amsterdam,","place":["The Netherlands"]},{"name":"Amsterdam Public Health research institute, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora L","family":"Swart","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,10,1]]},"reference":[{"issue":"Suppl. 7","key":"2024103012562934300_jphp12757-cit-0001","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","article-title":"Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Baccarani","year":"2012","journal-title":"Ann Oncol"},{"key":"2024103012562934300_jphp12757-cit-0002","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","article-title":"Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia","volume":"69","author":"Giles","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"2024103012562934300_jphp12757-cit-0003","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"2024103012562934300_jphp12757-cit-0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib","volume":"87","author":"Tanaka","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2024103012562934300_jphp12757-cit-0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","article-title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges","volume":"99","author":"Noens","year":"2014","journal-title":"Haematologica"},{"key":"2024103012562934300_jphp12757-cit-0006","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"2024103012562934300_jphp12757-cit-0007","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"2024103012562934300_jphp12757-cit-0008","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"2024103012562934300_jphp12757-cit-0009","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0b013e31819e91ce","article-title":"Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls","volume":"31","author":"Edelbroek","year":"2009","journal-title":"Ther Drug Monit"},{"key":"2024103012562934300_jphp12757-cit-0010","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.4155\/bio.13.156","article-title":"Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions","volume":"5","author":"De Kesel","year":"2013","journal-title":"Bioanalysis"},{"key":"2024103012562934300_jphp12757-cit-0011","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchromb.2012.07.011","article-title":"Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry","volume":"903","author":"Kralj","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2024103012562934300_jphp12757-cit-0012","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.4155\/bio.15.101","article-title":"DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application","volume":"7","author":"Antunes","year":"2015","journal-title":"Bioanalysis"},{"key":"2024103012562934300_jphp12757-cit-0013","volume-title":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine [Online]","author":"Guidance for Industry: Bioanalytical Method Validation","year":"2001"},{"key":"2024103012562934300_jphp12757-cit-0014","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation \u2013 a revisit with a decade of progress","volume":"17","author":"Shah","year":"2000","journal-title":"Pharm Res"},{"key":"2024103012562934300_jphp12757-cit-0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1081\/JLC-100101455","article-title":"Bioanalytical liquid chromatography method validation. A review of current practices and procedures","volume":"23","author":"Rosing","year":"2000","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"2024103012562934300_jphp12757-cit-0016","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0731-7085(95)01634-1","article-title":"Issues in evaluation of bioanalytical method selectivity and drug stability","volume":"14","author":"Dadgar","year":"1995","journal-title":"J Pharm Biomed Anal"},{"key":"2024103012562934300_jphp12757-cit-0017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jchromb.2005.11.009","article-title":"Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis","volume":"830","author":"Matuszewski","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2024103012562934300_jphp12757-cit-0018","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem"},{"key":"2024103012562934300_jphp12757-cit-0019","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2024103012562934300_jphp12757-cit-0020","volume-title":"European Public Assessment Report Tasigna Product Information","year":"2016"},{"key":"2024103012562934300_jphp12757-cit-0021","volume-title":"Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline___ond Edition","author":"NCCLS","year":"2002"},{"key":"2024103012562934300_jphp12757-cit-0022","volume-title":"Committee for Medicinal Products for Human Use and European Medicines Agency [Online]","author":"Guideline on Bioanalytical Method Validation","year":"2001"},{"key":"2024103012562934300_jphp12757-cit-0023","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1021\/ac303014b","article-title":"Prediction of the hematocrit of dried blood spots via potassium measurement on a routine clinical chemistry analyzer","volume":"85","author":"Capiau","year":"2013","journal-title":"Anal Chem"},{"key":"2024103012562934300_jphp12757-cit-0024","first-page":"1307","volume":"56","author":"Nijenhuis","year":"2016","journal-title":"The use of dried blood spots for pharmacokinetic monitoring of vemurafenib treatment in melanoma patients"},{"key":"2024103012562934300_jphp12757-cit-0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/jcph.558","article-title":"Dried blood spot analysis for therapeutic drug monitoring of pazopanib","volume":"55","author":"de Wit","year":"2015","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/10\/1265\/60231187\/jphp12757.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/10\/1265\/60231187\/jphp12757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:26:45Z","timestamp":1730312805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/69\/10\/1265\/6127735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,1]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,1]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12757","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,10,1]]}}}